Skip to main content
Log in

Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Introduction

Among other lipid related biomarkers, lipoprotein-associated phospholipase A2 (Lp-PLA2) and type II secretory phospholipase A2 (sPLA2) represent emerging candidates for refined assessment of future cardiovascular disease (CVD) risk. Indeed, emerging evidence from more than prospective 15 studies conducted since 2000, clearly demonstrate the prognostic ability of increased Lp-PLA2 concentrations or elevated activity for risk of future coronary heart disease (CHD) and stroke. Moreover, Lp-PLA2 might have similar predictive power for both, incident CHD in initially healthy subjects, as well as for recurrent events in those with clinically manifest atherosclerosis.

Discussion

By contrast, to date, there are only few prospective studies that have investigated the relationship of sPLA2 with future CVD risk. However, most of them show a positive association between increased mass or elevated activity and future atherosclerotic complications. Nonetheless, since inhibitors of Lp-PLA2 and sPLA2 have already been developed, these enzymes may be considered as novel therapeutic targets to treat residual risk in certain high risk patient groups.

Conclusion

This review summarizes the epidemiologic evidence on the association between increased mass or elevated activity of these two phospholipases and risk of CVD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stafforini DM. Biology of lipoprotein-associated phospholipase A2. Cardiovasc Drugs Ther. 2008;in press.

  2. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008;101:S41–50.

    Article  CAS  Google Scholar 

  3. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148–55.

    Article  PubMed  CAS  Google Scholar 

  4. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302–6.

    Article  PubMed  CAS  Google Scholar 

  5. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837–42.

    Article  PubMed  CAS  Google Scholar 

  6. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903–8.

    Article  PubMed  CAS  Google Scholar 

  7. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570–5.

    Article  PubMed  CAS  Google Scholar 

  8. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007;27:1788–95.

    Article  PubMed  CAS  Google Scholar 

  9. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008;51:913–9.

    Article  PubMed  CAS  Google Scholar 

  10. Jenny NS, Solomon C, Cushman M, Nelson JJ, Tracy RP, Psaty BM, et al. Lipoprotein-associated phospholipase A2 and cardiovascular disease: results from the Cardiovascular Health Study. Circulation 2006;113:E–332. Abstract.

    Google Scholar 

  11. Caslake MJ, Cooney J, Murray E, Bedford D, Robertson M, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly. Atheroscler Suppl 2006;7:484. Abstract.

    Article  Google Scholar 

  12. O’Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006;113:1745–52.

    Article  PubMed  CAS  Google Scholar 

  13. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007;28:699–704.

    Article  PubMed  CAS  Google Scholar 

  14. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26:2517–22.

    Article  PubMed  CAS  Google Scholar 

  15. Möckel M, Müller R, Vollert JO, Müller C, Danne O, Gareis R, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 2007;96:604–12.

    Article  PubMed  CAS  Google Scholar 

  16. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2004;26:137–44.

    Article  PubMed  CAS  Google Scholar 

  17. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586–93.

    Article  PubMed  CAS  Google Scholar 

  18. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006;52:1331–8.

    Article  PubMed  CAS  Google Scholar 

  19. Sabatine MS, Morrow DA, O’Donoghue M, Jablonksi KA, Rice MM, Solomon S, et al. PEACE Investigators. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2463–9.

    Article  PubMed  CAS  Google Scholar 

  20. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007;53:1440–7.

    Article  PubMed  CAS  Google Scholar 

  21. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479–84.

    Article  PubMed  CAS  Google Scholar 

  22. Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Hsia J, Hendrix SL, et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008;51:1115–22.

    Article  PubMed  CAS  Google Scholar 

  23. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166:2073–80.

    Article  PubMed  CAS  Google Scholar 

  24. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159–65.

    Article  PubMed  CAS  Google Scholar 

  25. The Lp-PLA2 Studies Collaboration. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3–11.

    Article  Google Scholar 

  26. Hurt-Camejo E, Camejo G, Peilot H, Oörni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001;89:298–304.

    Article  PubMed  CAS  Google Scholar 

  27. Jaross W, Eckey R, Menschikowski M. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 2002;32:383–93.

    Article  PubMed  CAS  Google Scholar 

  28. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem 2000;275:22895–904.

    Article  PubMed  CAS  Google Scholar 

  29. Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2000;20:1276–82.

    PubMed  CAS  Google Scholar 

  30. Webb N. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther. 2008; in press.

  31. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280–4.

    PubMed  CAS  Google Scholar 

  32. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000;86:718–22.

    Article  PubMed  CAS  Google Scholar 

  33. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824–32.

    Article  PubMed  CAS  Google Scholar 

  34. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005;46:1249–57.

    Article  PubMed  CAS  Google Scholar 

  35. Koenig W, Vossen CY, Mallat Z, Brenner H, Tedgui A, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2008;28. Abstract Supplement.

  36. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25:839–46.

    Article  PubMed  CAS  Google Scholar 

  37. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women. The EPIC-NORFOLK Study. Arterioscler Thromb Vasc Biol 2007;27:1177–83.

    Article  PubMed  CAS  Google Scholar 

  38. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949–52.

    Article  PubMed  Google Scholar 

  39. Rosenson RS. Emerging therapies that reduce phospholipase activity and implications for atherogenesis. Cardiovasc Drugs Ther. 2008;in press.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wolfgang Koenig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koenig, W., Khuseyinova, N. Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence. Cardiovasc Drugs Ther 23, 85–92 (2009). https://doi.org/10.1007/s10557-008-6135-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-008-6135-6

Key words

Navigation